In summary, this study confirmed the significant, but manageable treatment-related toxicities of the immunotherapy including pain, ARs, hypotension and capillary leak syndrome observed in the ANBL0032 study, patterned the dramatic increase in cytokine release during immunotherapy, validated the excellent EFS and OS rates of this immunotherapy combination treatment (1) and implicated the chemokine CXCL9 as mildly prognostic at pretreatment. The gene discussed is CXCL9; the disease is capillary leak syndrome.